Omnicell (NASDAQ:OMCL) Issues FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 1.650-1.850 for the period, compared to the consensus EPS estimate of 1.790. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Omnicell Trading Up 1.2 %

Shares of OMCL stock opened at $44.38 on Thursday. The firm has a fifty day moving average price of $44.60 and a 200 day moving average price of $43.22. The company has a market cap of $2.06 billion, a P/E ratio of -113.79, a PEG ratio of 30.78 and a beta of 0.78. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74.

Analyst Ratings Changes

Several brokerages recently issued reports on OMCL. Bank of America dropped their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. JPMorgan Chase & Co. boosted their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Barclays boosted their price target on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $52.33.

Insider Transactions at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.64% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.